For years, many seniors and retirees have faced a frustrating reality: popular GLP-1 medications like Wegovy and Zepbound could cost well over $1,000 per month if prescribed strictly for weight loss. That financial barrier left many Medicare beneficiaries feeling stuck, especially as obesity-related health conditions continued driving up medical costs and reducing quality of life. Now, Medicare’s new transitional policies are creating a possible path toward lower out-of-pocket costs for eligible patients through a temporary initiative known as the Medicare GLP-1 Bridge program. The changes could dramatically reduce monthly medication expenses for qualifying beneficiaries beginning in mid-2026, while also laying the groundwork for broader long-term coverage in the future.
